Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Investigation Report on China's Botulinum Toxin Type A Market, 2018-2022 Featuring Allergan & Lanzhou - ResearchAndMarkets.com

Research and Markets
Posted on: 08 Jan 19

The "Investigation Report on China's Botulinum Toxin Type A Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering

On Apr. 15, 2002, Botulinum Toxin Type A was approved by the FDA as a medical cosmetic that is injected to temporarily improve the appearance of moderate to severe glabellar lines. Later, some generic drugs appeared on the market. In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.

In China, the medical use of Botulinum Toxin Type A is to treat adult blepharospasm and prosopospasm and some strabismuses, especially acute paralytic strabismus, concomitant strabismus, strabismus caused by endocrine diseases, and the strabismus that cannot be corrected surgically for those aged 12 and above. The incidence of facial neuropathy is increasing in China. Many people are attacked by prosopospasm when they are over-stressed or fatigued. Seeing global annual incidence of about 0.003%, facial neuropathy is more common in women than in men, and more common in middle-aged and elderly people than in people from other age groups.

However, more users of Botulinum Toxin Type A are women who pursue a thin face or less wrinkles. With more than 10 million cosmetic surgeries every year, the market size of medical beauty in China has exceeded USD 10 billion and is still growing. As the demand for Botulinum Toxin Type A is expanding, some medical institutions and beauty salons have begun to inject Botulinum Toxin Type A smuggled from South Korea, France, Germany, etc. for their customers. Although the Chinese government only approved the sale of Botox and Hengli, smuggled Botulinum Toxin Type A products are easily available in China.

It is expected that, with the development of China's economy, the rise of income, and the change of consumption habit, Chinese people will spend more in medical beauty, and the market size of Botulinum Toxin Type A will continue to grow in China in the next few years.

Key Topics Covered:

1 Relevant Concepts of Botulinum Toxin Type A

2 Sales of Botulinum Toxin Type A in China, 2013-2017

3 Analysis on Major Manufacturers of Botulinum Toxin Type A in China, 2013-2017

4 Prices of Botulinum Toxin Type A in China, 2017-2018

5 Prospect of China's Botulinum Toxin Type A Market, 2018-2022

Companies Mentioned

  • Allergan
  • Lanzhou

For more information about this report visit https://www.researchandmarkets.com/research/3g5zb7/investigation?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005501/en/

Business Wire
www.businesswire.com

Last updated on: 08/01/2019

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.